# HRT and Menopause



Mr N Pisal Consultant Gynaecologist Whittington & Portland Hospital

### Menopause and HRT

Sexual Health



### Screening

Bone Health





### Menopause and HRT



### **Menopausal Symptoms**

- 94% get some symptoms, 25% get severe symptoms
- Hot flushes & sweats
- 74% experience, most common symptom
- Headaches
- Tiredness
- Irritability
- Poor memory
- Sleep disturbance
- Depression, anxiety, Mood swings
- Loss of libido
- Dry skin
- Vaginal atrophy
- Osteoporosis....



- Very effective at treating symptoms of menopause.
- Until recent studies (Women's Health Initiative and Million Women Study), HRT was widely used for long periods



# HRT scare prompted by 'flawed' studies

#### David Derbyshire

Hannah Devlin Science Editor

the gender stereotype of playing with dolls or are more likely to seek out

"tomboy" activities, scientists have

Polly Carmichael, an endocrinolo-gist at Great Ormond Street Hospital,

said that there was growing evidence

that hormones in early development

could have a permanent influence on gender identity and behaviour. The

findings challenge the view that giving

your child a "gender neutral" upbring-

ing could prevent stereotypes arising in

the first place. "There's now good evi-

dence that hormone exposure has an

ied girls born with a syndrome called

congenital adrenal hyperplasia (CAH),

who have been exposed to a large dose

of testosterone in the womb. As a result

the children are often born with "male-

influence," she said. Dr Carmichael has extensively stud-

THE MANTIMES CHELTENHAMFESTIVALS Hundreds of thousands of women

to grow up into tomboys

have suffered needlessly over the past decade because of the HRT scare, a hormone specialist said yesterday. Helen Buckler, an endocrinologist at SCIENCE 13 the University of Manchester, said that Until June 9 there was an emerging consensus that hormone replacement therapy was safe for most women under 60. Buy tickets at cheltenhamfestivals.com/

The studies that triggered the scare The studies that triggered the scare II years ago by claiming a link with breast cancer and heart disease were flawed or not applicable in the UK, she told the Cheltenham Science Festival. science

she said.

Research UK warned that the treatcancer and urged women to reduce the dose and duration of treatment.

hormones oestrogen and progesterone

Her comments come just days after the raised by studies in 2002 and 2003 both studies. "The feeling is now that Her comments come just days after the British Menopaue Society published. The first, the US women's like US women's like to US women's like to US women's like to US women's like to set of the protection we guidance stating that the begin the US women's like to set of the protection of HRT outweighed the r, c ancer women in ther Go amen in ther Go and the set cancer , heart through as a consensus view."

disease and stroke Cancer Research UK, appeared to field problems with the WHI findings sweats depression and loss of sex drive sweats depression and loss of sex drive it works by replacing the female set women use the drug, compared with average age of the menopause is 52.

The following year the Million Climacteric, the journal of the Inter-

older women. The therapy cut the risks

take HRT have an increased risk of Susan Jebb, head of population breast cancer, but that risk returns to health at the Cambridge unit, said it normal around five years after stop-

study was also flawed. The 1.3 million

Leading article, page 32

Fears about the safety of HRT were analyses had questioned the findings of Fizzy drinks leave a bitter The girls who are destined like" genitalia, but are now normally Chris Smith Health Correspondent

assigned a female gender at birth. She said that girls with the condition influences whether girls conform to provide a natural control group for usary a only dura di a tudying the extent to which biological risk of heart disease and diabetes even fluence gender roles, compared with the impact of social factors. "Their be-haviour is more boyish in terms of their are on the road to serious illness later choice of playmates and self identity." harmful fats in their blood. Switching

Dr Carmichael cited one study that showed that girls with CAH were more likely to prefer toys that are usually chosen by boys, such as vehicles and weapons, and have greater interest in latest study is the first to show children

The same study showed that, while in general, boys and girls of primary Research Council Human Nutrition school age have 80-90 per cent of playmates of the same sex, girls with CAH do not appear to show a preference for playing with one sex over the other cent of their favourite playmates were tes and heart disease. girls and about 50 per cent were boys.

are at risk rough-and-tumble play. Research Unit at Cambridge University, said. "Our findings suggest drinkyoung people on a path to the early


### The study found that about 50 per development of risk factors for diabe-

Her team followed 1,433 Australian their habits early.

aftertaste for the young


	RR (E2 only)	RR (E+P)
CHD	0.91	1.29
Stroke	1.39	1.41
Breast Cancer	0.77	1.26
PE	1.34	2.13
Colorectal Ca	1.08	0.63
Hip Fracture	0.61	0.66

### Selected clinical outcomes by participant age



JAMA 2004;291:1701-1712

### WHI studies: Coronary heart disease HRT and CHD: absolute risk by age





Page 1 of 11



BMJ 2012;345:e6409 doi: 10.1136/bmj.e6409



# Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial

Louise Lind Schierbeck *registrar*<sup>1</sup>, Lars Rejnmark *associate professor, consultant*<sup>2</sup>, Charlotte Landbo Tofteng *staff specialist 1*<sup>1</sup>, Lis Stilgren *consultant*<sup>3</sup>, Pia Eiken *consultant, senior endocrinologist*<sup>4</sup>, Leif Mosekilde *professor, senior consultant*<sup>2</sup>, Lars Køber *professor, consultant*<sup>5</sup>, Jens-Erik Beck Jensen *associate professor, consultant*<sup>1</sup>


<sup>1</sup>Department of Endocrinology, Hvidovre Hospital, Kettegård alle 30, 2650 Hvidovre, Denmark; <sup>2</sup>Department of Medicine and Department of Endocrinology and Internal Medicine, Århus University Hospital, Åarhus, Denmark; <sup>3</sup>Department of Endocrinology, Svendborg Hospital, Svendborg, Denmark; <sup>4</sup>Department of Cardiology, Nephrology, and Endocrinology, Hillerød Hospital, Hillerød, Denmark; <sup>5</sup>Department of Cardiology, Rigshospitalet, Copenhagen, Denmark

Main outcome measure The primary endpoint was a composite of death, admission to hospital for heart failure, and myocardial infarction.

**Results** At inclusion the women on average were aged 50 and had been postmenopausal for seven months. After 10 years of intervention, 16 women in the treatment group experienced the primary composite endpoint compared with 33 in the control group (hazard ratio 0.48,95%confidence interval 0.26 to 0.87; P=0.015) and 15 died compared with

### The Danish Osteoporosis Prevention Study (DOPS)

Primary endpoint and mortality and major risks for HRT in the total population during randomisation phase (up to year 2002).



- Combined HRT increased breast cancer risk more that Oestrogen only HRT
- Risk increases with duration of HRT
- Risk seems to go back to normal within 5 y of stopping HRT

	RR (E2 only)	RR (E+P)
CHD	0.91	1.29
Stroke	1.39	1.41
Breast Cancer	0.77	1.26
PE	1.34	2.13
Colorectal Ca	1.08	0.63
Hip Fracture	0.61	0.66

# Risk for post-menopausal women (mean age 63) developing breast cancer over a five year period (15 out of 1000)

1000 people					
********	<b></b>	*********	*********		
	* * * * * * * * * * * * * * *	<b>+</b> + + + + + + + + + + + + + + + + + +	* * * * * * * * * * * * * * * *		
********	*********	********	********	*******	
\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	
*********	*********	*********	*********	*********	
	*********	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	************	***********	
					<b>``S</b>
					ir :
***********	* * * * * * * * * * * * *	00000000000000000000000000000000000000	* * * * * * * * * * * * *	* * * * * * * * * * * * * *	
*********	********	********	********	********	Li
	********				
	**********	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	***********	00000000000000000000000000000000000000	
*********			*********		

\*\*\*\*\*\*\*\*\*

...........

..........

. . . . . . . .

..........

Risk to general population




Additional risk for cc HRT users: 4 cases / 1000 (Not significant in latest analysis)

Significant <u>reduction</u> in breast cancer risk in CEE alone study"


La Croix AZ et al JAMA 2011; 305:1305-14

### Breast cancer risk: The progestogen matters!



### "Breast cancer risk was lower with natural progesterone / dydrogesterone"

Fournier A et al. Breast Cancer Res Treat 2008;107:103–11; Lyytinen H et al. Obst Gyn 2009;113:65–73.



*Figure 5:* Standardised incidence rates for endometrial cancer per 1000 women in the study cohort over a 5-year period, according to body-mass index and type of HRT last used

Risk in current users is 3-4 x higher than in non-users one case in 5000 users per year

The baseline risk of VTE between the ages of 50 and 70 is higher

Increased risk appears to be concentrated in new users

VTE risk is not increased with transdermal E (oral 3.5 vs TRD 0.9) ESTHER study - Lancet 2003;362:428-432

	Pooled O R	Pooled 95% CI
Observational studies Oral oestrogen	2.5	1.9-3.4
Transdermal	1.2	0.9-1.7
Randomised controlled trials Oral oestrogen	2.1	1.4-3.1

- Urogenital Atrophy<sup>1</sup>
  - Highly effective for vaginal and urinary symptoms
- Cognitive<sup>2</sup>
  - 30% reduction in dementia incidence if HRT started early
- Colon Cancer<sup>3</sup>
  - 44% reduction in CEE + P WHI (RR 0.56 0.38-0.81)

- Estradiol gel or patch
  - Estradot patches 25-100mcg
  - Oestrogel 2-4 apps
  - Sandrena gel 0.5-2.0mg/day
- Progesterone/Progestogens
  - Oral: Utrogestan cc100mg, sc200mg 12/28
  - Vaginal: Utrogestan, Crinone 8%, Cyclogest
  - Mirena
- Closest combined oral regimen
  - Femoston range 1:10, 2:10, Conti 1:5, Conti low dose 0.5:2.5

- Mirena: HRT / PMS (4yr license)
  - NB: poss prog SEs / bleeding
- "On the way" "Baby" Mirena 12 & 16 mcg systems (3y & 5y)

- Vaginal symptoms may persist despite HRT
- Highly effective for local symptoms
- Vagifem now licensed for indefinite usage

- Creams
  - Ovestin (0.1% estriol) / Gynest (0.01% estriol)
- Rings
  - Oestradiol: Estring 2 yr license
- Vag Tabs
  - Vagifem (10mcg) Total dose = 1.14mg/year

- Combined HRT has different profile compared to oestrogen alone (lipids, CHD)
- An increase in **breast cancer** risk is related to
  - the duration of use and
  - concurrent use of progestogens.
- Transdermal oestrogen have different metabolic profiles and side-effects (VTE risk)
- Mirena or Utrogestan + Transdermal Oestrogen

- Active ingredient Tibolone
- Mimics action of Oestrogen + Progesterone + Testosterone
- Bleed-free
- Can be used after 54 or 2 years after menopause
- Increases risk of breast cancer (but thought to be less than combined HRT)

### HRT should be part of the overall strategy

- Increase weight-bearing exercise
- Calcium + VitD3 supplements (Adcal D3)
- Reduce alcohol intake
- Quit smoking



# **Bone Health**

- Affects two million women in the UK
- 300,000 people in the UK suffer a fragility fracture per year including
  - 76,000 hip fractures
- Numbers increasing

- H/o fracture following a minor fall
- Early menopause (aged less than 45)
- H/o amenorrhoea > 1yr
- Smoking + alcohol
- Corticosteroids for three months or more
- Rheumatoid arthritis or coeliac disease
- BMI < 19

- Minimal radiation from a DEXA scan, less than one-tenth the dose of a standard chest X-ray.
- Safe and relatively inexpensive
- Baseline study at 50y of age + repeat every three years

- FRAX tool
  - Early detection and treatment
- Regular weight-bearing exercise
- Adcal D3
- Reduce risk of falling / improve balance etc

### WHI: Grade A evidence of fracture risk reduction with HRT in hip and spine<sup>1</sup>


- Regulatory View 2013
  - Minimum effective dosage for shortest duration with annual reappraisal
  - HRT should be used for prevention of **osteoporosis** only in women who are unable to use other medicines that are authorised for this purpose.....
- Menopause/Osteoporosis/Endocrine Society View
  - HRT should be used first line in women younger than 60y for prevention and Rx of osteoporosis

1. T. J. de Villiers and J. C. Stevenson The WHI: the effect of hormone replacement therapy on fracture prevention Climacteric June 2012; 15(3): 263



### Screening after 50

- CA125
- TVS
- Only 85% of all and 50% of early ovarian cancers will have raised CA125
- False positives with endometriosis, fibroids etc
- There will be a proportion of interval cancers even if you screen annually
- Screening can be used where risk is increased





### **Red Flag Symptoms**

- Post-menopausal bleeding
- New onset of pelvic or abdominal pain
- Persistent abdominal distension (women often refer to this as 'bloating')
- Feeling full (early satiety) and/or loss of appetite
- Increased urinary urgency and/or frequency.



### **Sexual Health and Contraception**

- Low libido
- Vaginal dryness
- Increased risk of STI

2 February 2012 St BMJ editorial: Sexual health and the older adult

- Less likely to use condoms
- Less likely to be screened
- More likely to start a new relationship
- Atrophic vaginitis: Risk of tears and transmission
- Immune senescence

- Intrinsa patch 300microgram/24hr
- Twice weekly testosterone patch
- Testim gel (1 pea-sized blob to be applied once a day or once every other day, 1 tube should last for at least 8 days)
- Livial

- Atrophic vaginitis
- Local oestrogen pessaries, cream or ring
- Vagifem 10mcg vaginal tablets or ovestin cream
  - Once at night for two weeks
  - Followed by twice a week for maintenance

• Lubrication such as Sylk / KY

- Vaginal symptoms may persist despite HRT
- Highly effective for local symptoms
- Vagifem now licensed for indefinite usage

- Creams
  - Ovestin (0.1% estriol) / Gynest (0.01% estriol)
- Rings
  - Oestradiol: Estring 2 yr license
- Vag Tabs
  - Vagifem (10mcg) Total dose = 1.14mg/year

- HRT indicated for menopausal symptoms
- Breast cancer risk seems to be associated with long term use oral progesterone ? could be avoided with Mirena
- Transdermal oestrogen reduces risk of VTE
- Oestrogel: Ability to easily titrate the dose with symptoms
- STI on the increase in this age group
- Prevention of osteoporosis
- Screening with CA125 + TVS for ovarian cancer, but has limitations

# Thank You

London Gynaecology Limited The Portland Hospital 212-14 Great Portland Street London W1W 5QN

Secretary: Marion Browne M: 07971 200 832 T : 020 8367 8999 F : 020 8082 5667

contact@london-gynaecology.com

www.london-gynaecology.com



15/08/2014